Title

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Intervention/Treatment

    clascoterone ...
  • Study Participants

    708
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Study Started
Jan 21
2016
Primary Completion
Apr 11
2018
Study Completion
Apr 11
2018
Results Posted
Nov 20
2020
Last Update
Nov 20
2020

Drug CB-03-01 cream, 1%

CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

  • Other names: cortexolone 17α-propionate, clascoterone (USAN, INN)

Drug Vehicle cream

Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.

CB-03-01 cream Experimental

CB-03-01 cream, 1% applied twice daily for 12 weeks

Vehicle cream Placebo Comparator

Vehicle cream applied twice daily for 12 weeks

Criteria

Inclusion Criteria:

Subject is male or non-pregnant female, 9 years of age or older. Females must be post-menopausal, surgically sterile, or using highly effective birth control methods. Women of child-bearing potential must have a negative urine pregnancy test (UPT) at the Screening/Baseline Visit.
Subject has provided written and verbal informed consent/assent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing.
Subject has an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4 (severe) [0 (clear) to 4 (severe) scale].
Subject has facial acne vulgaris with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones).
Subject and parent/guardian (if applicable) are willing to comply with study instructions and return to the clinic for required visits.
Subject has used the same type and brand of make-up, other facial products (exclusive of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.

Exclusion Criteria:

Subject is pregnant, lactating, or is planning to become pregnant during the study.
Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
Subject has greater than two (2) facial nodules.
Subject has nodulocystic acne.
Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
Subject is currently enrolled in an investigational drug or device study.
Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (Baseline).
Subject has facial hair that could interfere with the study assessments in the opinion of the investigator.
Subject and parent/guardian (if applicable) are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits.
Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.
Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.
Subject has used any of the prohibited topical anti-acne treatments or procedures prior to the study unless appropriate washout period is documented.
Subject has used used any of the prohibited systemic anti-acne medications prior to the study unless appropriate washout period is documented.

Summary

CB-03-01 Cream

Vehicle Cream

All Events

Event Type Organ System Event Term CB-03-01 Cream Vehicle Cream

Change From Baseline in Inflammatory Lesion Counts

Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

CB-03-01 Cream

-19.3
Inflammatory Lesions (Mean)
95% Confidence Interval: -21.1 to -17.5

Vehicle Cream

-15.5
Inflammatory Lesions (Mean)
95% Confidence Interval: -17.3 to -13.6

Change From Baseline in Non-inflammatory Lesion Counts

Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

CB-03-01 Cream

-19.4
Non-inflammatory Lesions (Mean)
95% Confidence Interval: -22.6 to -16.7

Vehicle Cream

-13.0
Non-inflammatory Lesions (Mean)
95% Confidence Interval: -15.7 to -10.3

Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

CB-03-01 Cream

18.4
Percentage of participants

Vehicle Cream

9.0
Percentage of participants

Percent Change From Baseline in Non-inflammatory Lesion (NIL) Counts

Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.

CB-03-01 Cream

-30.6
percent change (Mean)
95% Confidence Interval: -35.6 to -25.7

Vehicle Cream

-21.6
percent change (Mean)
95% Confidence Interval: -26.4 to -16.8

Percent Change From Baseline in Inflammatory Lesion (IL) Counts

Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.

CB-03-01 Cream

-44.8
percent change (Mean)
95% Confidence Interval: -49.0 to -40.5

Vehicle Cream

-36.5
percent change (Mean)
95% Confidence Interval: -40.8 to -32.2

Change From Baseline in Total Lesion Counts

Absolute change from Baseline in total lesions counts in each treatment group at Week 12.

CB-03-01 Cream

-39.1
Total lesions (Mean)
95% Confidence Interval: -43.0 to -35.1

Vehicle Cream

-28.8
Total lesions (Mean)
95% Confidence Interval: -32.6 to -24.9

Percent Change From Baseline in Total Lesion Counts

Percent change from Baseline in total lesions counts in each treatment group at Week 12.

CB-03-01 Cream

-37.0
percent change (Mean)
95% Confidence Interval: -40.9 to -33.2

Vehicle Cream

-28.4
percent change (Mean)
95% Confidence Interval: -32.3 to -24.6

Local Site Reactions

Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).

Outcome Measure Data Not Reported

Total

708
Participants

Age, Continuous

19.9
years (Mean)
Standard Deviation: 6.7

Baseline Acne Lesion Counts

Baseline Acne Lesion Counts

Baseline Acne Lesion Counts

Baseline IGA

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Sex: Female, Male

Overall Study

CB-03-01 Cream

Vehicle Cream

Drop/Withdrawal Reasons

CB-03-01 Cream

Vehicle Cream